Lotus Pharmaceutical Co. Ltd. announced that the Lenalidomide Capsules, 2.5 mg and 5 mg (generic version of BMS/Celgene Corporations Revlimid), jointly developed with Fuji Pharma Co. Ltd., has received approval from Japan Pharmaceuticals and Medical Devices Agency (PMDA).

According to IQVIA data, the total sales of Revlimid in Japan were approximately USD282 million for the 12 months ended December 31, 2022. As of Second Quarter 2023, apart from BMS, only Sawai Pharmaceutical Co. Ltd. has obtained PMDA approval for generic Lenalidomide.

But, to date, there is no generic lenalidomide sold in the Japanese market.